Bimekizumab Efficacy through Year 1 in Patients with Moderate to Severe Plaque Psoriasis Who Had Not Achieved a PASI 90 Response by Week 16: A Pooled Analysis from Four Phase 3/3B Trials. J of Skin [Internet]. 2024 Mar. 18 [cited 2026 Apr. 17];8(2):s369. Available from: https://skin.dermsquared.com/skin/article/view/2701